Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $4.1 million.

  • Contineum Therapeutics' Accumulated Expenses rose 789.89% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 789.89%. This contributed to the annual value of $6.7 million for FY2024, which is 5304.45% up from last year.
  • Per Contineum Therapeutics' latest filing, its Accumulated Expenses stood at $4.1 million for Q3 2025, which was up 789.89% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Accumulated Expenses registered a high of $6.7 million during Q4 2024, and its lowest value of $2.5 million during Q2 2024.
  • In the last 3 years, Contineum Therapeutics' Accumulated Expenses had a median value of $4.0 million in 2025 and averaged $4.3 million.
  • In the last 5 years, Contineum Therapeutics' Accumulated Expenses soared by 5304.45% in 2024 and then plummeted by 2583.82% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Accumulated Expenses stood at $4.4 million in 2023, then surged by 53.04% to $6.7 million in 2024, then plummeted by 38.94% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $3.7 million for Q2 2025, and $3.8 million during Q1 2025.